Holen Sie sich die Stockscreener-App
1.14
1.72%
-0.02
Handel nachbörslich:
1.14
Schlusskurs vom Vortag:
$1.16
Offen:
$1.15
24-Stunden-Volumen:
74,715
Relative Volume:
0.16
Marktkapitalisierung:
$56.86M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-0.7808
EPS:
-1.46
Netto-Cashflow:
$-54.55M
1W Leistung:
-8.06%
1M Leistung:
-8.80%
6M Leistung:
-44.93%
1J Leistung:
-44.12%
1-Tages-Spanne:
$1.12
$1.17
1-Wochen-Bereich:
$1.09
$1.255
52-Wochen-Spanne:
$0.931
$3.42
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Vergleichen Sie AKYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.14 | 61.85M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
558.06 | 199.19B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.03 | 49.82B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
86.93 | 42.71B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
249.69 | 35.94B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.58 | 15.12B | 2.90B | 467.20M | 306.90M | 6.37 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Craig Hallum | Buy → Hold |
| 2024-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Buy |
| 2022-11-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-06-22 | Eingeleitet | BTIG Research | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
Deutsche Bank AG Raises Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences (AKYA) Receives Price Target Cut from Morgan Stanley | AKYA Stock News - GuruFocus
Northern Trust Corp Buys 39,799 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Spatial proteomics Market Worth Observing Growth: Bruker, Akoya Biosciences, PerkinElmer - newstrail.com
Spatiotemporal Omics Market Research Report 2025-2035, Competitive Analysis of Prominent Players10X Genomics, Akoya Biosciences, Bruker, Curio Bioscience, IonPath, MGI, and RareCyteResearchAndMarkets.com - FinancialContent
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of “Hold” from Brokerages - Defense World
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Akoya Biosciences (AKYA) Soars on New Acquisition Proposal - GuruFocus
An undisclosed buyer agreed to acquire Akoya Biosciences, Inc.. - marketscreener.com
Akoya Biosciences Receives Unsolicited Buyout Offer From Third Party - marketscreener.com
Akoya stock surges as new buyout bid risks Quanterix deal (AKYA) - Seeking Alpha
Akoya Biosciences reviews unsolicited acquisition proposal By Investing.com - Investing.com Nigeria
Akoya Biosciences IncOn May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing - marketscreener.com
Akoya Biosciences reviews unsolicited acquisition proposal - Investing.com
Akoya Biosciences (NASDAQ:AKYA) Given New $1.08 Price Target at Canaccord Genuity Group - Defense World
Akoya Biosciences Reports Q1 2025 Financial Results - TipRanks
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKY - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Sto - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Faces Uncertainty Amid Merger and Marke - GuruFocus
Akoya Biosciences, Inc. SEC 10-Q Report - TradingView
Akoya: Q1 Earnings Snapshot - The Washington Post
Akoya Biosciences earnings missed by $0.11, revenue fell short of estimates - Investing.com Canada
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akoya Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akoya Biosciences Inc Reports Q1 2025 Earnings: EPS of -$0.18 Be - GuruFocus
Akoya Biosciences Reports First Quarter 2025 Financial Results - The Manila Times
Akoya Biosciences (AKYA) Projected to Post Quarterly Earnings on Monday - Defense World
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc.AKYA - Business Wire
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Acquired by JPMorgan Chase & Co. - Defense World
Quanterix and Akoya Biosciences Announce Amended Merger Agreement - ADVFN
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Recommendation of “Hold” by Analysts - Defense World
Canaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
AKYA Merger Faces Backlash Amid Shareholder Discontent | AKYA St - GuruFocus
Quanterix Acquisition of Akoya Biosciences (AKYA) Faces Challenges | AKYA Stock News - GuruFocus
Kent Lake Issues Statement on Quanterix?s Amendment to Merger with Akoya Biosciences - marketscreener.com
Quanterix, Akoya Biosciences Amend Merger Deal - marketscreener.com
Akoya stock falls on amended Quanterix merger deal (AKYA) - Seeking Alpha
Quanterix Revises Merger Terms with Akoya Biosciences - TipRanks
Merger Amendment: Changes to Quanterix and Akoya Biosciences (AK - GuruFocus
Quanterix And Akoya Biosciences Announce Amended Merger Agreement - marketscreener.com
Canaccord Adjusts Price Target for Akoya Biosciences (AKYA) | AK - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (NasdaqPPBI), Southern States Bancshares, Inc. (NasdaqSSBK), Akoya Biosciences, Inc. (NasdaqAKYA) - TradingView
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Res - GuruFocus
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Research | AKYA Stock News - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development - Investing.com Australia
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - The Manila Times
Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akoya Biosciences Inc-Aktie (AKYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):